Researchers in Switzerland and the United States have combined bioengineered human skin with bioprinted cartilage to produce what in the future could be perfect-looking ears to replace the outer shell ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...
Palvella Therapeutics, Inc. (NASDAQ: PVLA) on Monday shared topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) for cutaneous venous malformations ...
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage pipeline aimed at some of the most underserved rare skin ...
Capillary Malformation-Arteriovenous Malformation (CM-AVM) syndrome is a rare, autosomal dominant vascular disorder characterised by the presence of multifocal capillary malformations that may occur ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results